What is the debt of Solid Biosciences this year?
Solid Biosciences has a debt level of -72.31 USD this year.
In 2024, Solid Biosciences's total debt was -72.31 USD, a -52.74% change from the -153 USD total debt recorded in the previous year.
Solid Biosciences's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Analyzing Solid Biosciences's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Investors pay close attention to Solid Biosciences’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Shifts in Solid Biosciences’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Solid Biosciences has a debt level of -72.31 USD this year.
The debt of Solid Biosciences has increased by -52.74% compared to the previous year dropped.
High debt can pose a risk for investors of Solid Biosciences, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
Low debt means that Solid Biosciences has a strong financial position and is able to fulfill its obligations without overburdening its finances.
An increase in debt of Solid Biosciences can adversely affect the financial condition of the company and result in a higher burden on its finances.
A reduction in debt of Solid Biosciences can strengthen the company's financial position and improve its ability to meet its financial obligations.
Some factors that can influence the debt of Solid Biosciences include investments, acquisitions, operating costs, and revenue development.
The debts of Solid Biosciences are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
To change the debt, Solid Biosciences can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
Over the past 12 months, Solid Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Solid Biosciences is expected to pay a dividend of 0 USD.
The current dividend yield of Solid Biosciences is .
Solid Biosciences pays a quarterly dividend. This is distributed in the months of .
Solid Biosciences paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Solid Biosciences is assigned to the 'Health' sector.
To receive the latest dividend of Solid Biosciences from 10/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/3/2024.
The last dividend was paid out on 10/3/2024.
In the year 2023, Solid Biosciences distributed 0 USD as dividends.
The dividends of Solid Biosciences are distributed in USD.
Our stock analysis for Solid Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Solid Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.